Roflumilast and Cognition

Effects of Roflumilast on Cognition in Healthy Adults: a Behaviour-EEG Study

The aim of the current project is to validate PDE4 inhibitors as a target for cognition enhancers (proof-of-concept) using a translational behaviour-EEG approach. The project will demonstrate whether memory, but also attention, information processing or executive function improves with the PDE4 inhibitor roflumilast in healthy humans.

Inclusion Criteria:

• 18 to 35 years of age
• Healthy (i.e. absence of all exclusion criteria), normal static binocular acuity (corrected or uncorrected),
• Body mass index between 18.5 and 30
• Willingness to sign an informed consent.
• Positive evaluation on the memory screening

Exclusion Criteria:

• History of cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal, haematological, or psychiatric illness
• First-degree relative with psychiatric disorder (in particular major depressive disorder and suicidality)
• Excessive drinking (>20 glasses of alcohol containing beverages per week)
• Pregnancy or lactation
• Use of chronic medication other than oral contraceptives
• Use of recreational drugs in the 2 weeks preceding participation
• Smoking
• Orthostatic hypotension
• Lactose intolerance
• Sensory or motor deficits which could reasonably be expected to affect test performance